Cooper J F
Urol Clin North Am. 1980 Oct;7(3):653-65.
A novel radioimmunochemical method for the measurement of human prostatic acid phosphatase in serum and bone marrow has demonstrated distinct biochemical advantages over the standard enzymatic techniques that are currently utilized in the clinical laboratory. The promising nature of the immunochemical assay now in clinical assessment for prostatic cancer may lend itself particularly to more sensitive confirmation of the presence of prostatic neoplasia as well as significantly more precision in the clinical staging of the disease process. In its present form, utilization of the technique as a reliable screening test for early prostatic cancer is patently inappropriate from a biochemical and biostatistical point of view. Continuing research on the antigenic nature of the human prostatic acid phosphatase molecule and the development of antibody with enhanced specificity may somewhat resolve the current screening problem. However, the essentially insoluble problem of the relatively low prevalence rate for prostatic cancer in males in the United States will persist and will probably limit the clinical application of enzymatic and radioimmunochemical screening techniques for early prostatic cancer.
一种用于测量血清和骨髓中人类前列腺酸性磷酸酶的新型放射免疫化学方法，已显示出相对于临床实验室目前使用的标准酶促技术具有明显的生化优势。目前正在对前列腺癌进行临床评估的免疫化学测定法的前景，可能特别有助于更敏感地确认前列腺肿瘤的存在，以及在疾病进程的临床分期中显著提高精确度。就其目前的形式而言，从生物化学和生物统计学的角度来看，将该技术用作早期前列腺癌的可靠筛查试验显然是不合适的。对人类前列腺酸性磷酸酶分子的抗原性质进行持续研究以及开发具有更高特异性的抗体，可能会在一定程度上解决当前的筛查问题。然而，美国男性前列腺癌相对较低的患病率这一基本无法解决的问题将持续存在，并且可能会限制酶促和放射免疫化学筛查技术在早期前列腺癌临床应用中的应用。
